mRNA Therapeutics Market Size & Growth Forecast 2027–2036, By Segments (Type, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

mRNA Therapeutics Market size stood at USD 14.2 billion in 2026 and is predicted to grow at a 16.15% CAGR from 2027 to 2036, exceeding USD 63.46 billion by 2036. The industry revenue for 2027 is estimated at USD 16.13 billion.

• Base Year Value (2026): USD 14.2 billion
• CAGR (2027-2036): 16.15%
• Forecast Year Value (2036): USD 63.46 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

mRNA Therapeutics Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America captured 42.79% of the market in 2026, supported by advanced biotechnology capabilities, established clinical research infrastructure, and efficient commercialization pathways for therapeutic development.
  • Asia Pacific is projected to grow at a 19.15% CAGR, driven by expanding biopharmaceutical capacity, rising biologics investment, stronger translational research, and increasing adoption of advanced therapeutic platforms.

• Segment Momentum:

  • Prophylactic applications held a 93.1% market share in 2026, supported by established preventive use, broad population targeting, scalable deployment, and alignment with public health delivery models.
  • Hospitals & Clinics are experiencing the fastest growth because they provide the infrastructure for administration, patient monitoring, storage, and specialized care, enabling wider clinical adoption of mRNA therapeutics.

• Market Expansion Drivers:

  • Expanding clinical trial activity accelerating commercialization of mRNA therapeutics across chronic disease applications.
  • Advancements in mRNA delivery technologies improving therapeutic stability, safety, and large-scale manufacturing efficiency.
  • Increasing biopharmaceutical partnerships strengthening investment in personalized mRNA-based therapeutic development pipelines.

• Leading Market Participants:

  Leading players in the mRNA therapeutics market include Moderna, Inc. (United States), BioNTech SE (Germany), Pfizer Inc. (United States), CureVac N.V. (Germany), Sanofi S.A. (France), GlaxoSmithKline plc (United Kingdom), AstraZeneca PLC (United Kingdom), Arcturus Therapeutics Holdings Inc. (United States), Ethris GmbH (Germany), CSL Seqirus (Australia).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 14.2 billion
  • 2027 Estimated Market Size: USD 16.13 billion.
  • Projected Market Size: USD 63.46 billion by 2036
  • Growth Forecasts: 16.15% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Prophylactic (Type) | Hospitals & Clinics (End-use) | Infectious Diseases (Application)
  • Emerging Opportunity Segment: Therapeutic (Type) | Hospitals & Clinics (End-use) | Oncology (Application)

Market Growth Drivers and Industry Trends

Expanding clinical trial activity accelerating commercialization of mRNA therapeutics across chronic disease applications

Increasing clinical trial activity will drive the mRNA therapeutics market as researchers broaden the investigation of messenger RNA-based approaches beyond established applications into chronic and complex diseases. Clinical development is helping evaluate the ability of mRNA platforms to deliver therapeutic proteins, modulate biological pathways, and support disease-specific treatment strategies. As evidence from clinical programs accumulates, pharmaceutical developers are gaining greater opportunities to advance mRNA candidates through development and commercialization pathways.

Advancements in mRNA delivery technologies improving therapeutic stability, safety, and large-scale manufacturing efficiency

The mRNA therapeutics market is being strengthened by advances in delivery technologies that address important challenges associated with RNA stability, cellular uptake, and targeted administration. Improved delivery systems can protect mRNA molecules from degradation while enabling more efficient transport into intended cells, supporting therapeutic activity at appropriate sites. Progress in formulation and manufacturing processes is also helping developers establish more consistent production workflows and improve the scalability of mRNA-based products.

Increasing biopharmaceutical partnerships strengthening investment in personalized mRNA-based therapeutic development pipelines

Increasing collaboration across the biopharmaceutical sector will boost the mRNA therapeutics market by combining specialized capabilities in RNA research, delivery technologies, clinical development, and manufacturing. Partnerships can distribute development risks while providing access to complementary technologies and research expertise, encouraging broader investment in therapeutic pipelines. Personalized approaches are particularly supported by these collaborations because mRNA platforms can be designed around specific biological targets and disease characteristics.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Expanding clinical trial activity accelerating commercialization of mRNA therapeutics across chronic disease applications	2.00%	High	North America, Europe	High	Near Term
Advancements in mRNA delivery technologies improving therapeutic stability, safety, and large-scale manufacturing efficiency	1.70%	Moderate	North America, Asia Pacific	High	Mid Term
Increasing biopharmaceutical partnerships strengthening investment in personalized mRNA-based therapeutic development pipelines	1.30%	Moderate	Asia Pacific, North America	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America accounted for the largest share of the mRNA therapeutics market at 42.79% in 2026, reflecting its mature biotechnology ecosystem, advanced pharmaceutical research capabilities, and strong infrastructure for developing innovative nucleic acid-based therapies. The region has a well-developed clinical research environment and established expertise in mRNA design, delivery technologies, manufacturing, and regulatory development. Continued investment in next-generation vaccines and therapeutic applications is broadening the potential use of mRNA platforms beyond infectious diseases, including oncology and other complex medical conditions, thereby reinforcing regional market leadership.

Asia Pacific represents the fastest-growing region, supported by expanding biopharmaceutical manufacturing capacity, increasing healthcare investment, and growing interest in advanced therapeutic platforms. Governments and healthcare institutions across the region are strengthening biotechnology capabilities, while domestic research activity and technology adoption are supporting the development of localized mRNA production and clinical applications. Improvements in healthcare infrastructure and rising demand for innovative treatments are further encouraging investment in mRNA technologies, positioning Asia Pacific as an increasingly important growth center for the market.

Key Country Insights

United States

Platform Innovation Center

The U.S. mRNA therapeutics market is characterized by continuous investment in platform technologies, clinical development, and manufacturing scale-up. Companies in the U.S. prioritize expanding therapeutic applications while strengthening production capabilities for diverse disease targets.

Japan

Precision Therapeutic Development

Japan's mRNA therapeutics market emphasizes targeted treatment development supported by strong pharmaceutical research capabilities. Organizations invest in delivery technologies and product quality to address complex therapeutic applications across multiple disease areas.

South Korea

Biotech Commercialization Drive

South Korea is expanding the mRNA therapeutics market through biotechnology investment and partnerships across research and manufacturing. Companies focus on strengthening development pipelines while enhancing production flexibility for future therapeutic programs.

Germany

Manufacturing Technology Excellence

Germany supports the mRNA therapeutics market through advanced biopharmaceutical production and process optimization capabilities. Industry participants focus on scalable manufacturing, quality assurance, and research collaborations that accelerate therapeutic development.

France

Research Collaboration Network

France advances the mRNA therapeutics market through collaboration between biotechnology firms, research institutes, and healthcare organizations. Development efforts prioritize innovative therapeutic candidates supported by efficient clinical research ecosystems.

Italy

Specialized Development Capabilities

Italy contributes to the mRNA therapeutics market through pharmaceutical research, contract development, and specialized manufacturing expertise. Italian organizations focus on supporting therapeutic innovation while reinforcing quality-driven production processes.

Segment Leadership and Growth Trends

 

Type Segment Analysis: Prophylactic (Largest Segment) vs Therapeutic (Fastest-Growing Segment)

The prophylactic segment dominated the mRNA therapeutics market in 2026, accounting for a 93.1% share, supported by the strong role of mRNA-based approaches in preventing infectious diseases through rapid and targeted immune responses. The segment benefits from the ability of mRNA platforms to facilitate antigen production within cells while offering development flexibility and scalable manufacturing potential. Continued emphasis on disease prevention, vaccine innovation, and adaptable therapeutic platforms further reinforces the leading position of prophylactic applications.

Therapeutic applications are gaining momentum as mRNA technology expands beyond preventive immunization into treatments designed to address a broader range of diseases. Advances in personalized medicine, cancer-focused applications, protein replacement, and regenerative approaches are supporting interest in therapeutic mRNA, while improvements in delivery technologies and formulation stability are helping broaden its potential clinical use.

End-use Segment Analysis: Hospitals & Clinics (Largest & Fastest-Growing Segment)

Hospitals & clinics held the largest share of the mRNA therapeutics market in 2026, accounting for 48.08%, while also representing the fastest-growing end-use segment. Their leading position reflects the concentration of specialized healthcare infrastructure, clinical expertise, diagnostic capabilities, and treatment administration within these settings. Hospitals and clinics are particularly important for emerging mRNA-based therapies because their multidisciplinary care environments can support advanced treatment protocols, patient monitoring, and the integration of innovative therapeutic approaches into clinical practice.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Prophylactic, Therapeutic	Prophylactic	Therapeutic
End-use	Hospitals & Clinics, Research Organizations, Others	Hospitals & Clinics	Hospitals & Clinics
Application	Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Others	Infectious Diseases	Oncology

Competitive Landscape and Market Positioning

Key companies in the mRNA therapeutics market:

1. Moderna Inc. (United States)

2. BioNTech SE (Germany)

3. Pfizer Inc. (United States)

4. CureVac N.V. (Germany)

5. Sanofi S.A. (France)

6. GlaxoSmithKline plc (United Kingdom)

7. AstraZeneca PLC (United Kingdom)

8. Arcturus Therapeutics Holdings Inc. (United States)

9. Ethris GmbH (Germany)

10. CSL Seqirus (Australia)

The mRNA therapeutics market is rapidly advancing through development of next-generation genetic medicine platforms aimed at addressing complex diseases. Continuous innovation in delivery systems and molecular design is improving therapeutic precision and effectiveness. The market is increasingly driven by breakthroughs in RNA-based medicine technologies.

Industry Development/News

Company Name	Date	Key Development
Eli Lilly	Apr-26	Eli Lilly entered a definitive agreement to acquire Kelonia Therapeutics in a transaction valued at up to $7 billion. This acquisition, featuring a $3.25 billion upfront payment, secures Kelonia’s proprietary in vivo gene placement system (iGPS), designed to enable the production of CAR-T cells directly within the patient’s body, thereby bypassing complex and costly ex vivo manufacturing requirements.
Oxford Nanopore Technologies and Lonza	May-26	Oxford Nanopore Technologies and Lonza launched a joint quality control solution specifically designed to modernize and accelerate GMP testing for mRNA therapeutics. This collaborative initiative aims to streamline analytical workflows and improve the efficiency of manufacturing release testing, ultimately facilitating faster development and more reliable production cycles for mRNA-based medical products.
ParcelBio	May-26	Programmable mRNA startup ParcelBio secured $13 million in new funding to advance its proprietary platform. The capital is designated for extending the expression duration of mRNA and expanding therapeutic applications into chronic disease treatments, marking a strategic effort to evolve beyond traditional vaccine-focused mRNA modalities.
ONI	Feb-26	ONI launched LNP PREP on its Aplo Flow platform, offering an automated, single-particle analysis workflow for lipid nanoparticle characterization. By integrating programmable fluidics with advanced microscopy, the solution enables more precise and scalable characterization, directly addressing critical bottlenecks in the development and manufacturing of mRNA delivery systems.
Samsung Biologics	Jan-26	Samsung Biologics America acquired a former GSK biologics facility for $280 million, marking the company’s strategic entry into the U.S. biopharmaceutical manufacturing market. The acquisition significantly expands its manufacturing footprint and enhances large-scale production capabilities, reinforcing its position as a major service provider in the global biologics and mRNA-related manufacturing ecosystem.
Reprogram Biosciences Inc.	May-26	Preclinical oncology firm Reprogram Biosciences Inc. closed a seed financing round, reaching $6 million in total funding since its 2025 inception. The investment provides the necessary capital to advance its early-stage pipeline focused on mRNA-based therapeutics for solid tumors, supporting the continued exploration of novel mRNA-driven cancer treatment approaches.